LRRK2 & Parkinson's - Drs. Behrouz, Alessi, Fell, Padmanabhan, and West

At this week's Round Table Discussion, Dr. Spring Behrouz, CEO and Co-Founder of Vincere Biosciences, discusses LRRK2's role in Parkinson's disease (PD) with experts Drs. Dario Alessi, Matthew Fell, Shalini Padmanabhan, and Andy West. #openscience #discussion #research #science #biology #brain #vincere #dundee #merck #michaeljfoxorg #duke #parkinsons #lrrk2 #therapeutics #aging Link to full articles: https://pubmed.ncbi.nlm.nih.gov/29855... https://pubmed.ncbi.nlm.nih.gov/38438... https://pubmed.ncbi.nlm.nih.gov/38368... https://pubmed.ncbi.nlm.nih.gov/34340... https://pubmed.ncbi.nlm.nih.gov/38293... https://pubmed.ncbi.nlm.nih.gov/31461... https://pubmed.ncbi.nlm.nih.gov/35895... Dr. Alessi's Profile: Profile: https://www.dundee.ac.uk/people/dario... Dr. Fell's Profile and Social Media: LinkedIn:   / matthew-fell-6936862   Twitter:   / mjfell1979   Dr. Padmanabhan's Social Media: LinkedIn:   / shalini-padmanabhan   Dr. West's Profile and Social Media: Profile: https://scholars.duke.edu/person/andr... Twitter:   / dukewestlab   Dr. Spring Behrouz Social Media: LinkedIn:   / bahareh   Twitter:   / dr_behrouz   Chapters: 00:00-02:14 Introduction 02:15-07:45 How LRRK2 Contributes to PD 07:46-11:30 LRRK2 and GBA 11:31-17:51 LRRK2 and Synuclein 17:52-22:25 LRRK2 and VPS35 22:26-29:34 LRRK2 and the Pink/parkin Pathway 29:35-36:13 LRRK2 and Cell Types 36:14-50:53 LRRK2 Therapeutics in Clinical Trials 50:54-56:11 LRRK2 Therapeutics and Idiopathic PD 56:12-56:33 Conclusion